兽用生物制品的运输、贮存与使用

对兽用生物制品的命名作了概述,并对免疫预防用制品、诊断用制品、治疗用制品的运输、贮存与使用分别进行了阐述,同时对改善我国兽用生物制品的监管提出了建议。     

Comparison of antibody values in sera of pigs vaccinated with a subunit or an attenuated vaccine against classical swine fever

Ten pigs, aged 85 days, were vaccinated with a subunit vaccine containing 32 g of classical swine fever virus glycoprotein E2 (gp E2) (group 1), and a further 10 pigs were vaccinated with a C strain vaccine (10^4±0.15 TCID₅₀/ml), produced by amplification in minipig kidney (MPK) cell culture (group 2). Nine non-vaccinated pigs served as a control group (group 3). Serum samples were collected before (day 0) and at 4, 10, 21 and 28 days after vaccination and were analysed by two commercially available enzyme immunoassays and by a neutralizing peroxidase-linked assay (NPLA). At the same times, peripheral blood was taken for determining the total leukocyte count and the body temperature was taken daily. Antibodies were not detected in serum samples collected before vaccination (day 0), and no side-effects that could be connected with vaccination were observed during the trial. Ten days after vaccination 6/10 pigs vaccinated with the subunit vaccine were seropositive. On days 21 and 28, the ratios of serologically positive to vaccinated pigs were 9/10 and 10/10, respectively. Four of the ten pigs that were vaccinated with the C strain vaccine were positive on day 21 and 9/10 on day 28. However, the results of the NPLA showed that only 4/10 pigs had an antibody titre >1:32 at the end of the trial in both the vaccinated groups, even though the subunit vaccine initiated an earlier and higher level of neutralizing antibodies than the vaccine produced from the C strain. Challenge was performed 28 days after vaccination on four randomly selected pigs from both vaccinated groups. The pigs survived the challenge without showing any clinical signs of classical swine fever (CSF), while two nonvaccinated control pigs died on the 10th and 12th days after infection.     

不同纯化浓缩方法制备的新城疫疫苗对SPF鸡免疫效果的研究

为研究利用不同纯化浓缩方法制备的新城疫疫苗对SPF鸡免疫效果的影响,试验取经过纯化浓缩的新城疫抗原制备的疫苗、经离心未经浓缩的抗原制备成的疫苗和经浓缩未离心的抗原制备成的疫苗分别免疫30日龄SPF鸡,免疫后分别在第7d、14 d、21 d、28 d、35 d、45 d、70 d、90 d采集血清检测新城疫抗体水平。结果表明,经浓缩纯化后抗原制备的疫苗与其他两组抗原制备的疫苗相比,物理外观性状基本相同,浓缩纯化后抗原制备的疫苗其单位抗原含量更高、杂质更少,抗体水平更高,统计数据显示差异显著。因此研究得出,浓缩倍数(即抗原含量)越高,抗体水平越高,持续的时间也越长。     

兔病毒性出血症、多杀性巴氏杆菌病、产气荚膜梭菌病(A)型三联灭活疫苗研制

对 5批兔病毒性出血症、多杀性巴氏杆菌病、产气荚膜梭菌病三联灭活疫苗进行了动物试验 ,结果表明该疫苗安全有效。近期效检对兔病毒性出血症的保护率为 1 0 0 % ,对兔多杀性巴氏杆菌病保护率为 92 % ,对产气荚膜梭菌病 (A)型保护率为 88%。在免疫期试验中 ,免疫 6个月后 ,对兔病毒性出血症保护率为 1 0 0 % ,对多杀性巴氏杆菌病的保护率为 79% ,对产气荚膜梭菌病 (A)型的保护率为 88%。在保存期试验中 ,4～ 8℃保存 1年仍有效。     

羊痘研究概况

羊痘病毒基因组庞大,约有150 kb,包括中间编码区和两端相同的反向末端重复序列;绵羊痘病毒和山羊痘病毒基因组彼此十分相似,约有96%的核苷酸完全相同.p32蛋白是目前世界各地分离鉴定的所有羊痘病毒株共有的且特异性很强的结构蛋白,在诊断和预防方面具有重要的应用价值.虽然羊疸从临床症状和宿主特异性上很客易做出诊断,但进一步的实验室确诊还是必要的,现已有多种检测方法和诊断试剂.控制该病最有效的方法是使用疫苗对易感动物进行免疫接种.文章从病原学、诊断和预防控制等方面对羊痘进行综述.     

Vaccination of Poultry Workers: Delivery and Uptake of Seasonal Influenza Immunization

Avian influenza is a highly infectious disease in poultry and although the risk of human infection is low, concerns exist that it could evolve into a new human strain of pandemic potential if reassortment with a human influenza virus occurs. In January 2007, the UK government introduced a programme to vaccinate poultry workers to reduce the potential of such an event. This study evaluates the delivery, uptake and costs of the programme in three counties of England. A questionnaire survey was completed by consultants in public health in all the Primary Care Trusts in Norfolk, Suffolk and Cambridgeshire in May 2007. The delivery of the programme varied between Primary Care Trusts, including being delivered in some cases by clinics in primary care, by general practitioners and occupational health services in others. The uptake of vaccination was low ranging from 7% to 29% at a cost of £29 to £132 per person vaccinated. Vaccination of poultry workers as a public health measure to prevent an influenza pandemic is likely to be ineffective with the level of coverage found in this evaluation in our region.     

腐蹄病C型节瘤拟杆菌纤毛蛋白基因T程疫苗对家兔的免疫试验

将转化C型节瘤拟杆菌纤毛蛋白基因表达子粒的工程菌PAK/2pfsC在含羧苄青霉素营养肉汤培养基中培养,用MgCl2法在培养物上清中提取表达产物(纤毛蛋白).将表达的纤毛蛋白产物用弗氏完全佐剂乳化,制成疫苗.用疫苗免疫3只健康家兔,21 d后再次接种;定期采血,用对流免疫电泳和K凝集实验检测试验家兔的体液免疫应答及抗体水平.结果发现,免疫7 d即可产生相应抗体,21 d后抗体效价达到8 000×以上,而且高滴度抗体可维持6个月以上.试验表明,腐蹄病C型节瘤拟杆菌纤毛蛋白基因工程疫苗具有较好的免疫应答和免疫原性.     

缓释复方免疫增强剂对鸡新城疫疫苗免疫增强效果研究

将40只10日龄海兰褐蛋雏鸡，随机分成试验组和对照组，每组20只，分别皮下注射ND-La Sota弱毒疫苗0．2ml／只。同时给试验组雏鸡投服缓释复方免疫增强剂1粒／只，对照组不投服。在免疫前、免疫后10、20、30和40d，每组随机取10只鸡采血，测定ND-HI抗体效价、T淋巴细胞ERFC形成率和ANAE阳性率。结果免疫后10、20、30、40d，试验组与对照组比较，鸡ND-HI抗体效价、T淋巴细胞ERFC形成率和ANAE阳性率差异极显著（P〈0．01）或显著（P〈0．05），三项指标具有相同的消涨趋势，表明缓释复方免疫增强剂可以提高鸡的体液免疫功能和细胞免疫功能。     

兔球虫疫苗的研究现状

兔球虫病是家兔最常见、危害最严重的疾病之一,国内外多采用抗球虫药物对兔球虫病进行预防和治疗。目前为止,我国还没有研制出商品化的兔球虫疫苗,国内外仅有少部分学者开展了兔球虫病疫苗的研究工作。主要对兔球虫疫苗活虫苗、亚单位苗、基因工程苗的研究进展进行综述,以期为兔球虫疫苗的相关研究提供参考。